New study dovetails earlier research showing improved COVID-19 recovery outcomes in individuals with higher K2 status.

Oslo, Norway and edison, NJ (1 October 2020) — A newly published paper1 in Biocatalysis and Agricultural Biotechnology from New Zealand researchers elucidates the association between K2 and recovery rates in individuals with COVID-19.

According to the authors, a “profound increase” in inactive matrix Gla protein (MGP) levels were observed in COVID-19 patients, indicating a poor K2 status and associated increased risk of mortality from comorbidities (e.g., obesity, diabetes, hypertension, and cardiovascular diseases).

MGP is dependent upon vitamin K2 menquinone-7 (MK-7) to become active, and the more circulating MGP that is active, the more calcification in arteries is inhibited. Vascular calcification is a process known to commence in elastin fibers, and elastin is a substantial player in ensuring tissues remain pliable and resilient. Elastic fibers are heavily present in lung tissue, where MGP, when activated, is considerably expressed – indicating the importance of MK-7 in supporting lung (pulmonary) function.

The researchers write: “Therefore, MK-7 deficiency can be a risk factor for increasing the severity of the COVID-19 disease, and SARS-CoV-2 infected patients with comorbid conditions tend to develop acute manifestations.”

This paper strengthens the concept that Vitamin K2 as MK-7 is a nutrient with substantial ability to protect pulmonary function during an active virus. It supports an earlier study published in April2 that evaluated MK-7 in 123 patients with COVID-19 and 184 controls, revealing a link between vitamin K2 deficiency and disease severity.

“Evidence continues to mount that MK-7’s mechanism of action has a considerable impact on protecting human health,” said NattoPharma Chief Medical Officer Dr. Hogne Vik. “Of course, a dietary supplement is not a cure or a treatment, but over time, MK-7 can fortify the body’s resilience to age-related conditions and viral infection. This is the second study that associates K2 status with outcomes in COVID-19 patients. More research in this area is warranted and necessary.”

NattoPharma ASA and its US subsidiary NattoPharma USA, Inc. continue to lead the research endeavors into MK-7 (as MenaQ7®) as well as global MenaQ7® product development.

References:

1 Berenjian A, Sarabadani Z, “How menaquinone-7 deficiency influences mortality and morbidity among COVID-19 patients” Biocatalysis and Agricultural Biotechnology 29 (2020) 101792
2 Dofferhoff, A.S.; Piscaer, I.; Schurgers, L.J.; Walk, J.; van den Ouweland, J.M.; Hackeng, T.M.; Lux, P.; Maassen, C.; Karssemeijer, E.G.; Wouters, E.F.; Janssen, R. Reduced Vitamin K Status as A Potentially Modifiable Prognostic Risk Factor in COVID-19. Preprints 2020, 2020040457 (doi: 10.20944/preprints202004.0457.v1).


XXX

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

Phone: 609-643-0749 x 220

E-mail: kate.quackenbush@nattopharma.com